SELLAS Life Sciences Group, Inc. (SLS)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| — | Q2-2026 | 8-K (2026-07-27) | ||
| 10-QLatest | Q1-2026 | 8-K (2026-05-12) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-19) · 99.1 | 8-K (2026-01-08) | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-20) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-13) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-13) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-14) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-28) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | ||
| 10-Q | Q2-2023 | 8-K (2023-08-10) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Stockholders' Equity | — |
|
| Consolidated Statement of Stockholders' (deficit) Equity | ||
| Consolidated Statement of Stockholders' Equity (deficit) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Acquired In-process Research and Development | — |
|
| Balance Sheet Accounts | ||
| Basis of Presentation and Significant Accounting Policies | ||
| Collaboration and In-license Agreements | — |
|
| Commitments and Contingencies | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Description of Business | — |
|
| Employee Benefit Plan | — |
|
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Legal Proceedings, Commitments and Contingencies | — |
|
| License Revenue With 3d Medicines, Inc. | — |
|
| Licensing Revenue | ||
| Liquidity | ||
| Liquidity and Going Concern | ||
| Organization and Description of Business | ||
| Pay Vs Performance Disclosure | ||
| Stock-based Compensation | ||
| Stockholders Equity | ||
| Stockholders Equity (deficit) | ||
| Stockholders' (deficit) Equity | — |
|
| Subsequent Events | ||
| Warrants To Acquire Shares of Common Stock | ||